SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy

An announcement from SciSparc Ltd. ( (SPRC) ) is now available.

On May 12, 2025, SciSparc Ltd. announced a significant development in its collaboration with Clearmind Medicine Inc., resulting in the publication of a European patent application for a psychedelic-based combination therapy targeting cocaine addiction. The patent application, based on preclinical trials, highlights the effectiveness of Clearmind’s MEAI and SciSparc’s Palmitoylethanolamide in reducing cocaine cravings without affecting natural reward responses. This publication adds to the ongoing patent efforts by SciSparc and Clearmind in the U.S. and other global territories, potentially strengthening their position in the pharmaceutical industry focused on addiction therapies.

More about SciSparc Ltd.

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focusing on developing therapies for central nervous system disorders and rare diseases. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. SciSparc also has a subsidiary that sells hemp seed oil-based products on Amazon.

Average Trading Volume: 4,122,726

Technical Sentiment Signal: Sell

Current Market Cap: $3.81M

See more insights into SPRC stock on TipRanks’ Stock Analysis page.